Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer. Genentech/Roche

Genentech, a member of the Roche Group presented positive results from the Phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Tecentriq in combination with Avastin reduced the risk of death (OS) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42-0.79; p=0.0006) and reduced the risk of disease worsening or death (PFS) by 41% (HR=0.59; 95% CI: 0.47-0.76; p<0.0001), compared with sorafenib. safety for tecentriq and avastin was consistent with the known safety profiles of the individual medicines.>

�For the first time in a decade, we are seeing a treatment that has improved overall survival for people with unresectable hepatocellular carcinoma compared with the current standard of care,� said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. �Tecentriq in combination with Avastin could transform the treatment of this aggressive disease, and we are working closely with global health authorities in the hope of bringing this treatment option to patients as soon as possible.�

These data will be presented in the Presidential session at the European Society for Medical Oncology (ESMO) Asia Congress 2019 on November 23 at 11:00 a.m. (Singapore Standard time) (Abstract LBA3).